Chemotherapy of metastatic colorectal cancer

Current Treatment Options in Gastroenterology

Volumn 8, Issue 3, 2005, Pages 239-247

  Saad, Everardo D ^a   Hoff, Paulo M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATROPINE; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CYTOCHROME P450 3A4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; KETOCONAZOLE; LOPERAMIDE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OXALIPLATIN; PRODRUG; TUBERCULOSTATIC AGENT; VASCULOTROPIN;

ACNE; AIRWAY OBSTRUCTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD TOXICITY; BULLOUS SKIN DISEASE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; DESQUAMATION; DIARRHEA; DRUG COST; DRUG DOSE REGIMEN; DRUG EXTRAVASATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DYSESTHESIA; EDEMA; ERYTHEMA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFLAMMATION; LARYNX DISORDER; LIVER METASTASIS; METASTASIS; NAUSEA; NEUTROPENIA; PAIN; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SKIN DEFECT; STOMATITIS; THROMBOSIS; URTICARIA;

EID: 21044455335     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0016-x     Document Type: Review

References (61)

1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999, 49:33-64.
2. Stewart BW, Kleihues P, editors. World Cancer Report. Lyon: IARC Press; 2003.
3. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
4. Gloeckler Ries LA, Reichman ME, Lewis DR, et al.: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003, 8:541-552.
5. Longley DB, Harkin DP, Johnston PC: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
6. Anonymous: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992, 10:896-903.
7. Thirion P, Michiels S, Pignon JP, et al.: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004, 22:3766-3775.
8. Anonymous: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998, 16:301-308.
9. Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000, 321:531-535.
10. Jonker DJ, Maroun JA, Kocha W: Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000, 82:1789-1794.
11. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
12. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
13. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
14. Hoff PM, Ansari R, Batist G, et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19:2282-2292.
15. Van Cutsem E, Twelves C, Cassidy J, et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19:4097-4106.
16. Anonymous: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992, 10:904-911.
17. Cunningham D, Pyrhonen S, James RD, et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418.
18. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004, 22:1209-1214.
19. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
20. Petrelli N, Herrera L, Rustum Y, et al.: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987, 5:1559-1565.
21. Poon MA, O'Connell MJ, Moertel CG, et al.: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7:1407-1418.
22. Saltz LB, Kanowitz J, Kemeny NE, et al.: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996, 14:2959-2967.
23. Falcone A, Di Paolo A, Masi G, et al.: Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 2001, 19:3456-3462.
24. Joel SP, Papamichael D, Richards F, et al.: Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. Clin Pharmacol Ther 2004, 76:45-54.
25. Brickell K, Porter D, Thompson P: Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports. Br J Cancer 2003, 89:615-616.
26. Anonymous: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998, 16:3537-3541.
27. Kolesar JM, Johnson CL, Freeberg BL, et al.: Warfarin-5-FU interaction - a consecutive case series. Pharmacotherapy 1999, 19:1445-1449.
28. Masci G, Magagnoli M, Zucali PA, et al.: Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003, 21:736-739.
29. Schrag D: The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004, 351:317-319.
30. Culy CR, Clemett D, Wiseman LR: Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000, 60:895-924.
31. deBraud F, Munzone E, Nole F, et al.: Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol 1998, 21:279-283.
32. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30.
33. Rothenberg ML, Oza AM, Bigelow RH, et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003, 21:2059-2069.
34. Gil-Delgado MA, Bastian G, Guinet F, et al.: Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Am J Clin Oncol 2004, 27:294-298.
35. Gamelin L, Boisdron-Celle M, Delva R, et al.: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10:4055-4061.
36. Lloyd Jones M, Hummel S, Bansback N, et al.: A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001, 5:1-128.
37. Sinha BK: Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 1995, 49:11-19.
38. Fuchs CS, Moore MR, Harker G, et al.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003, 21:807-814.
39. Kehrer DF, Mathijssen RH, Verweij J, et al.: Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002, 20:3122-3129.
40. Kuhn JG: Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Huntingt) 2002, 16:33-40.
41. Mathijssen RH, Verweij J, de Bruijn P, et al.: Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002, 94:1247-1249.
42. Rothenberg ML, Meropol NJ, Poplin EA, et al.: Mortality associated with irinotecan plus bolus fluorouracil /leucovorin: summary findings of an independent panel. J Clin Oncol 2001, 19:3801-3807.
43. Benson AB, 3rd, Ajani JA, Catalano RB, et al.: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004, 22:2918-2926.
44. Wasserman E, Myara A, Lokiec F, et al.: Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997, 8:1049-1051.
45. Hoff PM, Royce M, Medgyesy D, et al.: Oral fluoropoyrimidines. Semin Oncol 1999, 26:640-646.
46. Dooley M, Goa KL: Capecitabine. Drugs 1999, 58:69-76, discussion 77-78.
47. Schuller J, Cassidy J, Dumont E, et al.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000, 45:291-297.
48. Mackean M, Planting A, Twelves C, et al.: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998, 16:2977-2985.
49. Van Cutsem E, Hoff PM, Harper P, et al.: Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004, 90:1190-1197.
50. Abushullaih S, Saad ED, Munsell M, Hoff PM: Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002, 20:3-10.
51. Lin E, Morris JS, Ayers GD: Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Huntingt) 2002, 16:31-37.
52. Fabian CJ, Molina R, Slavik M, et al.: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990, 8:57-63.
53. Ward S, Kaltenthaler E, Cowan J, Brewer N: Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003, 7:1-93.
54. Jansman FG, Postma MJ, van Hartskamp D, et al.: Cost-benefit analysis of capecitabine versus 5-fluorouracil /leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004, 26:579-589.
55. Hoff PM, Ellis LM, Abbruzzese JL: Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? Oncology (Huntingt) 2004, 18:736-41, discussion 742, 745-6.
56. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
57. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
58. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
59. Mendelsohn J: The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8:3-9.
60. Saltz LB, Meropol NJ, Loehrer PJ, Sr., et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
61. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.